BioCentury
ARTICLE | Clinical News

Paquinimod: Phase II data

June 13, 2011 7:00 AM UTC

An exploratory, open-label, Swedish and Danish Phase II trial in 13 patients with mild active SLE showed that once-daily 1.5 and 3 mg oral paquinimod for 12 weeks as an add-on to standard therapy led ...